Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Simpinicline - Oyster Point Pharmaceuticals

Next Previous
Search
Drug Profile

Simpinicline - Oyster Point Pharmaceuticals

Alternative Names: OC-02; OC-02-cit; Simpinicline citrate; TC-6499-221

Latest Information Update: 30 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oyster Point Pharmaceuticals
  • Class Antivirals; Eye disorder therapies; Irritable bowel syndrome therapies; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Nicotinic receptor agonists; Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dry eyes; Irritable bowel syndrome
  • Preclinical COVID 2019 infections

Most Recent Events

  • 28 Oct 2024 Ji Xing Pharmaceuticals is now called Corxel Pharmaceuticals
  • 03 Jan 2023 Oyster Point Pharmaceuticals has been acquired by Viatris Inc
  • 11 Aug 2021 Clinical development ongoing in the US for dry eyes

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top